Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)
Optimizing and Personalizing interventions for schizophrenia Across the Lifespan (OPAL)
批准号:
10623751
负责人:
THOMAS SCOTT STROUP
金额:
$209.08万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-04-01 至 2028-06-30
关键词:
AccelerationAddressAdolescenceAdvocateAffectAreaAssertivenessAssessment toolAttentionBlack, Indigenous, People of ColorCaringCessation of lifeClinicClinicalClinical ResearchCognitionCognitiveCommunicationCommunitiesDataDementiaDevelopmentDiagnosisDiseaseEffectivenessEnsureEuropeFormulationFosteringGoalsHealthHealth TechnologyHomelessnessImpairmentIndividualInequityInfrastructureInterventionInterviewLongevityMeasurementMental HealthMethodologyMethodsMobile Health ApplicationNamesNew YorkOccupationalOutcomeParticipantPersonsPharmaceutical PreparationsPilot ProjectsPolicy MakerPremature MortalityProcessQualitative MethodsRecommendationRegimenResearch PersonnelResearch SupportResource AllocationResourcesRiskSafetySchizophreniaScientistServicesStrategic PlanningTarget PopulationsTestingTrainingTranslational ResearchTreatment EffectivenessUnited States Centers for Medicare and Medicaid ServicesWorkclinical translationcompare effectivenessdementia riskdisabilitydisability riskeffective interventionemerging adultend of lifeethnoracialevidence baseexperiencefeasibility testingfirst episode psychosisflexibilityhealth disparityimprovedindividualized medicineinnovationinterdisciplinary collaborationmHealthmood symptomnovelpeople of colorpersistent symptomperson centeredpersonalized interventionpersonalized medicinepractice settingprematurepsychotic symptomsreduce symptomsroutine practicesatisfactionservice deliveryshared decision makingside effectskillssocialsocial health determinantstooltraining opportunitytreatment optimizationtreatment strategy
中文摘要
OPAL中心以其为患有糖尿病的患者优化和个性化干预措施的目标而命名
英文摘要
The OPAL Center is named after its goal of Optimizing and Personalizing interventions for people with
schizophrenia Across the Lifespan. The target population for this ALACRITY Center is people diagnosed with
schizophrenia, which typically affects individuals from adolescence or early adulthood until the end of life.
Affected individuals commonly have impaired social and occupational functioning; experience persistent
psychotic and mood symptoms; have cognitive problems that may progress; and are at risk for disability and
premature death. Black, Indigenous, and People of Color (BIPOC) individuals are particularly at risk of poor
outcomes. The goal of this renewal application is to extend our efforts to accelerate the development and
implementation of effective, individualized treatments for schizophrenia in real clinical settings.
The specific aims of the Center renewal application are as follows:
1. Strengthen our infrastructure that supports research that examines innovative ways to optimize
treatments for people with schizophrenia throughout the lifespan and that accelerates the translation of clinical
research on schizophrenia to routine practice settings.
2. Conduct projects that develop, adapt, and test innovative, accessible, and person-centered interventions
that improve engagement in treatment and can be readily deployed.
3. Train scientists who will conduct translational research on interventions for schizophrenia.
The OPAL Signature Project will use 16 years of data (2007-2022) from the Center for Medicaid and
Medicare Services (CMS) to test hypotheses about risk factors for dementia among people diagnosed with
schizophrenia and compare the effectiveness of treatment strategies after diagnosis of dementia. We will then
integrate our findings to adapt a Cognitive Health Toolkit that provides assessment and management tools.
Exploratory Project 1 tests a novel, person-centered approach to assessment and treatment initiation
for BIPOC individuals with psychotic symptoms in community mental health clinics that incorporates an
adapted version of the Cultural Formulation Interview to improve diagnosis and treatment engagement.
Exploratory Project 2 will build on work done in Europe to adapt and test the feasibility and
preliminary effectiveness of Flexible Assertive Community Treatment (ACT), which will allow ACT teams to
allocate resources according to the individual needs of participants, improving efficiency and outcomes.
Exploratory Project 3 uses mobile health (mHealth) technology to deliver measurement-based care
and improve the person-centered outcomes of individuals with schizophrenia across the lifespan.
OPAL projects use the Center's common resources and methodologies to improve implementation and
personalization of treatments for important problems. Stakeholders help us to refine and adapt interventions for
effective implementation in real-world settings.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1007/s10597-021-00922-6
发表时间:
2022-08
期刊:
Community mental health journal
影响因子:
2.7
作者:
[Rolin SA, Scodes J, Dambreville R, Nossel IR, Bello I, Wall MM, Scott Stroup T, Dixon LB, Appelbaum PS]
通讯作者:
Appelbaum PS
DOI:
10.1176/appi.ps.202000863
发表时间:
2022-02-01
期刊:
Psychiatric services (Washington, D.C.)
影响因子:
--
作者:
[Smith TE, Haselden M, Corbeil T, Wall MM, Tang F, Essock SM, Frimpong E, Goldman ML, Mascayano F, Radigan M, Schneider M, Wang R, Rodgers I, Dixon LB, Olfson M]
通讯作者:
Olfson M
DOI:
10.1016/j.schres.2021.06.003
发表时间:
2022-05
期刊:
SCHIZOPHRENIA RESEARCH
影响因子:
4.5
作者:
[Hansen, Marie C., Lynch, David A., Stefancic, Ana, Medalia, Alice]
通讯作者:
Medalia, Alice
DOI:
10.1016/j.psychres.2022.114799
发表时间:
2022-11
期刊:
PSYCHIATRY RESEARCH
影响因子:
11.3
作者:
[Lynch, David A., Brown, Marie, Saperstein, Alice, Stefancic, Ana, Medalia, Alice]
通讯作者:
Medalia, Alice
DOI:
10.1016/j.schres.2021.03.006
发表时间:
2021-05
期刊:
Schizophrenia research
影响因子:
4.5
作者:
[Saperstein AM, Choi CJ, Jahshan C, Lynch DA, Wall M, Green MF, Medalia A]
通讯作者:
Medalia A
共 14 条
OPAL Center Administrative Core
-
批准号:10623752
-
项目类别:
-
资助金额:$87.99万
-
财政年份:2018
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
-
批准号:8018897
-
项目类别:
-
资助金额:$155.28万
-
财政年份:2009
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
-
批准号:8323933
-
项目类别:
-
资助金额:$238.07万
-
财政年份:2009
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
-
批准号:7882587
-
项目类别:
-
资助金额:$300.82万
-
财政年份:2009
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
-
批准号:8132232
-
项目类别:
-
资助金额:$299.74万
-
财政年份:2009
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMS
-
批准号:8465272
-
项目类别:
-
资助金额:$74.33万
-
财政年份:2009
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
CLINICAL MANAGEMENT OF METABOLIC PROBLEMS IN PATIENTS WITH SCHIZOPHRENIA:SW
-
批准号:7716895
-
项目类别:
-
资助金额:$0.13万
-
财政年份:2008
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
Addressing Challenges in Schizophrenia Research
-
批准号:6788858
-
项目类别:
-
资助金额:$17.04万
-
财政年份:2003
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
Addressing Challenges in Schizophrenia Research
-
批准号:7258786
-
项目类别:
-
资助金额:$17.2万
-
财政年份:2003
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
Addressing Challenges in Schizophrenia Research
-
批准号:7104210
-
项目类别:
-
资助金额:$17.15万
-
财政年份:2003
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
Addressing Challenges in Schizophrenia Research
-
批准号:6934565
-
项目类别:
-
资助金额:$17.17万
-
财政年份:2003
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
Addressing Challenges in Schizophrenia Research
-
批准号:6687909
-
项目类别:
-
资助金额:$17.21万
-
财政年份:2003
-
负责人:THOMAS SCOTT STROUP
-
依托单位:
海外基金